Translational Research in Genitourinary Oncology
Lines of Research
02.Development of new antineoplastic molecules in genitourinary tumours
03.Prognostic and predictive biomarkers in genitourinary cancer
04.Advanced therapies in uro-oncology
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Lozano, R; Lorente, D; Aragon, IM; Romero-Laorden, N; Nombela, P; Mateo, J; Reid, AHM; Cendon, Y; Bianchini, D; Llacer, C; Sandhu, SK; Sharp, A; Rescigno, P; Garces, T; Pacheco, MI; Flohr, P; Massard, C; Lopez-Casas, PP; Castro, E; de Bono, JS; Olmos, D – 2021
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study.
Martin-Bravo, C; Quiros, R; Blancas, I; Villatoro-Roldan, R; Robles, M; Alcaide, J; Navarro, V; Perez, D; Zarcos, I; Rivas-Ruiz, F; Perez-Ruiz, E; Quero, C – 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Sweeney, C; Bracarda, S; Sternberg, CN; Chi, KN; Olmos, D; Sandhu, S; Massard, C; Matsubara, N; Alekseev, B; Parnis, F; Atduev, V; Buchschacher, GL; Gafanov, R; Corrales, L; Borre, M; Stroyakovskiy, D; Alves, GV; Bournakis, E; Puente, J; Harle-Yge, ML; Gallo, J; Chen, G; Hanover, J; Wongchenko, MJ; Garcia, J; de Bono, JS – 2021
Apalutamide and Overall Survival in Prostate Cancer
Smith, MR; Saad, F; Chowdhury, S; Oudard, S; Hadaschik, BA; Graff, JN; Olmos, D; Mainwaring, PN; Lee, JY; Uemura, H; De Porre, P; Smith, AA; Brookman-May, SD; Li, S; Zhang, K; Rooney, B; Lopez-Gitlitz, A; Small, EJ – 2021
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
Cattrini, C; Espana, R; Mennitto, A; Bersanelli, M; Castro, E; Olmos, D; Lorente, D; Gennari, A – 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer
Lozano, R; Salles, DC; Sandhu, S; Aragon, IM; Thorne, H; Lopez-Campos, F; Rubio-Briones, J; Gutierrez-Pecharroman, AM; Maldonado, L; di Domenico, T; Sanz, A; Prieto, JD; Garcia, I; Pacheco, MI; Garces, T; Llacer, C; Romero-Laorden, N; Zambrana, F; Lopez-Casas, PP; Lorente, D; Mateo, J; Pritchard, CC; Antonarakis, ES; Olmos, D; Lotan, TL; Castro, E – 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
Conteduca, V; Wetterskog, D; Castro, E; Scarpi, E; Romero-Laorden, N; Gurioli, G; Jayaram, A; Lolli, C; Schepisi, G; Wingate, A; Casadei, C; Lozano, R; Brighi, N; Aragon, IM; Marin-Aguilera, M; Gonzalez-Billalabeitia, E; Mellado, B; Olmos, D; Attard, G; De Giorgi, U – 2021
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
Feng, FLY; Thomas, S; Saad, F; Gormley, M; Yu, MK; Ricci, DS; Rooney, B; Brookman-May, S; McCarthy, S; Olmos, D; Chowdhury, S; Hadaschik, B; Liu, Y; Davicioni, E; Smith, MR; Small, EJ – 2021
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer
Lorente, D; Llacer, C; Lozano, R; de Velasco, G; Romero-Laorden, N; Rodrigo, M; Sanchez-Iglesias, A; di Capua, C; Castro, E; Ferrer, C; Sanchez-Hernandez, A; Olmos, D – 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects
Aldea, M; Lam, L; Orillard, E; Perez, CL; Saint-Ghislain, M; Gravis, G; Flechon, A; Roubaud, G; Barthelemy, P; Ricci, F; Priou, F; Neviere, Z; Beaufils, M; Laguerre, B; Hardy, AC; Helissey, C; Ratta, R; Borchiellini, D; Pobel, C; Joly, F; Castro, E; Thiery-Vuillemin, A; Baciarello, G; Fizazi, K – 2021
Relationships of Gut Microbiota Composition, Short-Chain Fatty Acids and Polyamines with the Pathological Response to Neoadjuvant Radiochemotherapy in Colorectal Cancer Patients.
Sanchez-Alcoholado, L; Laborda-Illanes, A; Otero, A; Ordonez, R; Gonzalez-Gonzalez, A; Plaza-Andrades, I; Ramos-Molina, B; Gomez-Millan, J; Queipo-Ortuno, MI – 2021
DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review
Armstrong, N; Quek, RGW; Ryder, S; Ross, J; Forbes, C; Fox, KM; Castro, E – 2021
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva, L; Lozano, R; Llacer, C; Aragon, I; Pajares, BI; Saez, MI; Herrera-Imbroda, B; Montesa, A; Hernandez, D; Villatoro, R; Otero, A; Correa, R; Grau, G; Peinado, P; Pacheco, MI; Garcia-Galisteo, E; Rueda, A; Machuca, FJ; Alba, E; Marquez-Aragones, A; Olmos, D; Castro, E – 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations
Sokolova, AO; Marshall, CH; Lozano, R; Gulati, R; Ledet, EM; De Sarkar, N; Grivas, P; Higano, CS; Montgomery, B; Nelson, PS; Olmos, D; Sokolov, V; Schweizer, MT; Yezefski, TA; Yu, EY; Paller, CJ; Sartor, O; Castro, E; Antonarakis, ES; Cheng, HTH – 2021
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
del Alba, AG; Mendez-Vidal, MJ; Vazquez, S; Castro, E; Climent, MA; Gallardo, E; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Arranz, JA – 2021
GABAergic deficits in absence of LPA(1) receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus.
Rosell-Valle, C; Martinez-Losa, M; Matas-Rico, E; Castilla-Ortega, E; Zambrana-Infantes, E; Gomez-Conde, AI; Sanchez-Salido, L; de Guevara-Miranda, DL; Pedraza, C; Serrano-Castro, PJ; Chun, J; de Fonseca, FR; Alvarez-Dolado, M; Santin, LJ; Estivill-Torrus, G – 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1) an-label, 2 trial
de Bono, JS; Mehra, N; Scagliotti, GV; Castro, E; Dorff, T; Stirling, A; Stenzl, A; Fleming, MT; Higano, CS; Saad, F; Buttigliero, C; van Oort, IM; Laird, AD; Mata, M; Chen, HC; Healy, CG; Czibere, A; Fizazi, K – 2021
Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Perez-Ruixo, C; Ackaert, O; Ouellet, D; Chien, C; Uemura, H; Olmos, D; Mainwaring, P; Lee, JY; Yu, MK; Perez-Ruixo, JJ; Smith, MR; Small, EJ – 2020
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer
Cattrini, C; Soldato, D; Rubagotti, A; Zinoli, L; Zanardi, E; Barboro, P; Messina, C; Castro, E; Olmos, D; Boccardo, F – 2020
HSD3B1 (1245A > C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Khalaf, DJ; Aragon, IM; Annala, M; Lozano, R; Taavitsainen, S; Lorente, D; Finch, DL; Romero-Laorden, N; Vergidis, J; Cendon, Y; Oja, C; Pacheco, MI; Zulfiqar, M; Gleave, ME; Wyatt, AW; Olmos, D; Chi, KN; Castro, E – 2020
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

Bernardo Herrera Imbroda
-
Co-Investigadora ResponsableSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.

Elisa Matas Rico
Email: Elisa.matas@ibima.eu
ORCID
SCOPUS
-
Investigador/a SéniorSerán aquellos que tengan una actividad investigadora de al menos 5 años en la etapa posdoctoral. Estos investigadores estarán adscritos a un Grupo de Investigación liderado por un Investigador Responsable. Las funciones serán las que le tenga asignadas su IR.
Pueden liderar una línea de investigación de alguno de los grupos de investigación del Instituto, con financiación competitiva propia, y con potencial para llegar a convertirse responsable de un grupo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigador/a Asistencial Colaborador/aSerá Investigador Asistencial Colaborador el Investigador que no reúne la consideración de Investigador Posdoctoral. Estarán adscritos a un Grupo de Investigación liderado por un IR. Las funciones serán las que le tenga asignada su IR.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as posdoctorales y/o juniorEsta etapa posdoctoral estará restringida a Investigadores del Instituto que tengan el título doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque aún no hayan establecido un nivel significativo de independencia. Además, pueden tener actividades de docencia y/o asistencial más allá de su trabajo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Investigadores/as predoctorales y/o en formaciónSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staff
Los investigadores predoctorales y/o en formación serán aquellos investigadores que realizan investigaciones bajo supervisión en una línea de investigación orientada a la resolución de problemas de salud. Incluye aquellos investigadores que están cursando un doctorado (incluyendo a los contratados Río Hortega)
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.